Semaglutide (Ozempic®)

DRUG2 trials

Sponsors

Ministry of Health, Saudi Arabia, Rehman Medical Institute - RMI

Conditions

Type 1 Diabetes MellitusType 2 Diabetes

Phase 2

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

Not yet recruitingNCT07614412

Ministry of Health, Saudi ArabiaType 1 Diabetes Mellitus

Start: 2027-01-01End: 2028-12-31Target: 240Updated: 2026-05-29

Phase 4

Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial

CompletedNCT07732218

Rehman Medical Institute - RMIType 2 Diabetes

Start: 2022-07-04End: 2023-03-30Updated: 2026-07-28